Search Results
Your search for it matches 15487 pages
Showing 1001 - 1050Revumenib in High-Risk KMT2A-Rearranged Acute Leukemia
Patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2A gene, a genetic marker known as KMT2A, who were treated with revumenib, a small-molecule inhibitor of menin-KMT2A interactions, saw an overall response rate of 63%, according to results from...
Novel BET Inhibitor for Advanced Myelofibrosis
Researchers may have uncovered a new type of targeted therapy for patients with advanced myelofibrosis, according to new findings presented by Watts et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 750). Background Historically, there have been few...
Menin Inhibitors in Patients With Advanced AML and Gene Mutations
Two new studies have demonstrated positive results from novel therapies targeting menin for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) with specific gene mutations, according to findings presented by Jabbour et al (Abstract 57) and Issa et al (Abstract 58) at ...
Presence of MRD After Chemotherapy May Predict Benefit From Donor Transplant in NPM1-Mutated AML
Among patients who have acute myeloid leukemia (AML) with genetic mutations in NPM1, those with no residual leukemia cells in the blood based on high-sensitivity testing after two cycles of chemotherapy achieved high rates of overall survival at 3 years and saw no additional survival benefit from...
Daratumumab Plus VRd Outperforms VRd Alone for Multiple Myeloma
Newly diagnosed patients with multiple myeloma who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and dexamethasone (VRd) had significantly higher rates of survival without disease progression compared with those who received VRd alone. Results from the phase ...
AI Model May Help Distinguish Between Two Rare Hematologic Malignancies
A novel artificial intelligence (AI) model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia, according to new findings presented by Srisuwananukorn et al at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition...
CAR T-Cell Therapy Safe, Feasible for Patients With Lymphoma in Complete Remission Before Cell Therapy Begins
Data presented at the 2023 ASH Annual Meeting & Exposition suggest that chimeric antigen receptor (CAR) T-cell immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins (Abstract 615). While the findings do not answer the...
Autologous Stem Cell Transplant vs CAR T-Cell Therapy in Patients With Relapsed LBCL in Complete Remission
For patients with large B-cell lymphoma (LBCL) who have an early relapse or whose cancer doesn’t respond to first-line treatment, randomized trials have shown that chimeric antigen receptor (CAR) T-cell therapy is superior to the historical standard of care, which included additional chemotherapy...
Psychiatric and Substance Use Disorders May Be Linked to Poorer Outcomes in AML Following Venetoclax Combination Therapies
Researchers have found that patients with psychiatric or substance use disorders may have an increased risk of experiencing poorer outcomes such as early mortality following treatment for acute myeloid leukemia (AML) with venetoclax combination therapies compared with those without a recent history ...
Patients With Multiple Myeloma May Experience Poorer Outcomes in the Real World Compared With Reported Outcomes From Clinical Trials
Researchers identified a 75% higher rate of mortality among patients treated for multiple myeloma in real-world hospital settings compared with rates reported in clinical trials involving common therapies. The new findings were presented by Visram et al at the 2023 American Society of Hematology...
Male Researchers Lead the Majority of NIH’s Active R01 Grants in Classical Hematology Research
Investigators have found that in the past decade, a majority of the National Institutes of Health’s (NIH) active R01 grants related to classical, nonmalignant hematology were led by male investigators, according to new findings presented by Khan et al at the 2023 American Society of Hematology...
New Guideline Offers Much-Needed Support in the Treatment of Neuroendocrine Tumors
An ASCO guideline has been developed to inform the use of systemic treatments for metastatic, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).1 The guideline helps fill a knowledge gap among community oncologists in particular, who typically do not see many of these rare ...
Encorafenib Plus Binimetinib in Metastatic NSCLC With BRAF V600E Mutation
On October 11, 2023, the BRAF inhibitor encorafenib (Braftovi) with the MEK inhibitor binimetinib (Mektovi) was approved for patients with metastatic non–small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 The FDA...
Syed Ali Abutalib, MD, Moves to Advocate Health to Lead Hematology, Transplant Programs
Syed Ali Abutalib, MD, is taking his talents to the recently affiliated Aurora Health Care, now part of Advocate Health, one of the largest integrated health systems in the United States. He accepted a new position at Aurora St. Luke’s Medical Center in Milwaukee, where he is now Director of the...
Expert Point of View: Krishnansu Tewari, MD
Invited discussant Krishnansu Tewari, MD, Associate Professor in the Division of Gynecologic Oncology at the University of California, Irvine, said two new approaches for locally advanced cervical cancer, as described at the European Society for Medical Oncology (ESMO) Congress 2023, represent...
Chemotherapy Induction Before Chemoradiotherapy Improves Survival in Locally Advanced Cervical Cancer
In patients with newly diagnosed, locally advanced cervical cancer, induction chemotherapy prior to chemoradiation therapy led to a 35% reduction in the risk for disease recurrence or death (hazard ratio [HR] = 0.65; P = .013) and a 39% reduction in the survival hazard (HR = 0.61; P = .04),...
Expert Point of View: Kerin B. Adelson, MD, MHCDS
Discussant of these abstracts on the Oncology Care Model (OCM), Kerin B. Adelson, MD, MHCDS, Chief Quality and Value Officer at The University of Texas, MD Anderson Cancer Center, suggested the OCM was beneficial for both patients and health professionals despite the lack of clear positive ...
Expert Point of View: Bradley J. Monk, MD, FACS, FACOG
Based on the results of the phase III BEATcc trial, there is no longer doubt that immune checkpoint inhibitors have transformed the treatment landscape in cervical cancer—and there is no place for “skeptics” of this approach, according to Bradley J. Monk, MD, FACS, FACOG, Director and Principal...
On Mark Cuban and the Chemotherapy Crisis
Although significant progress has been made to reduce the gap in health outcomes of minority or underserved patients, meaningful steps forward still need to be made to improve health disparities. Countless studies have shown, in general, that affluent White individuals have better health outcomes...
Expert Point of View: Elizabeth Smyth, MD
ASCO discussant Elizabeth Smyth, MD, a consultant medical oncologist at Oxford University Hospitals National Health Service Foundation Trust in the United Kingdom, commented on the EDGE-Gastric trial. This regimen, which evaluated dual checkpoint blockade with next-generation agents, aims to...
Early Data Show Novel Immunotherapy Regimen May Improve Outcomes in Advanced Gastric Cancer
Initial findings from the global phase II EDGE-Gastric trial indicate the potential for two novel immune checkpoint inhibitors to improve outcomes in advanced gastroesophageal adenocarcinoma. The findings were reported at the November 2023 ASCO Plenary Session by Yelena Y. Janjigian, MD, Chief of...
Combining Ribociclib With Hormone Therapy Improves Patient Outcomes in Early-Stage Breast Cancer: NATALEE
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease–free survival benefits in patients with early-stage hormone receptor–positive, HER2-negative breast cancer at risk of disease recurrence. Results from the phase III NATALEE trial, led by researchers at The ...
Supportive Parents and Early Love of Science Lead to a Career in Hematology Oncology for Nina Shah, MD
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nina Shah, MD, Global Head of Multiple Myeloma Clinical Development and Strategy, Hematology, Oncology Research and Development at AstraZeneca. She is a hematologist who specializes in...
Abemaciclib Plus AI in Postmenopausal Patients With Advanced Breast Cancer: Final Overall Survival Analysis From MONARCH 3
Final overall survival results from the MONARCH 3 trial were reported in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-12). MONARCH 3 evaluated abemaciclib in combination with an aromatase inhibitor (AI) compared with an AI alone as initial...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
Invited discussant of TROPION-Lung01, Sarat Chandarlapaty, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, was cautiously optimistic about this new treatment option. “Dato-DXd [datopotamab deruxtecan] has a benefit over standard-of-care docetaxel in the second-line setting. There...
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
Some Breast Cancer Survivors May Safely De-escalate Mammography 3 Years After Surgery
Women aged 50 or older who had less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes as women who had annual mammography, according to results from the Mammo-50 trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-02)....
Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients With Low-Risk DCIS
Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable 5-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the 2023 San...
Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole
Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Understanding the Treatment Options for PD-1–Refractory Melanoma
For the treatment of advanced melanoma that is refractory to anti–PD-1 antibodies, there is no standard approach. The various options, with a look to the future, were discussed by Melinda L. Yushak, MD, MPH, Assistant Professor of Hematology and Oncology at Emory University School of Medicine, at...
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Almost all postmenopausal patients aged 50 to 69 with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 San...
Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Using fertility preservation and/or assisted reproductive technologies (ART) did not adversely impact 3-year cancer recurrence rates among patients with hormone receptor–positive breast cancer who paused endocrine therapy to become pregnant, according to results from the POSITIVE trial presented at ...
Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral...
Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11). Background...
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Neoadjuvant Chemotherapy May Help Some Patients With Breast Cancer Skip Regional Nodal Irradiation
For patients whose breast cancer converted from lymph node–positive to lymph node–negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation did not increase the risk of disease recurrence or death 5 years after surgery, according to results from the NRG...
Adding Durvalumab to Chemoradiotherapy in Locally Advanced Cervical Cancer
As reported in The Lancet Oncology by Bradley J. Monk, MD, and colleagues, the phase III CALLA trial showed no significant improvement in progression-free survival with the addition of durvalumab to chemoradiotherapy in previously untreated patients with locally advanced cervical cancer. Study...
Everolimus for Pediatric Recurrent/Progressive Low-Grade Glioma
In the phase II PNOC001 trial reported in the Journal of Clinical Oncology, Daphne A. Haas-Kogan, MD, MBA, and colleagues found that everolimus showed activity in pediatric patients with recurrent or progressive low-grade glioma. PI3K/AKT/mTOR pathway activation was not correlated with clinical...
Lung-MAP Trial Demonstrates Potential of Public-Private Partnerships in Advancement of Cancer Therapy
The unique public-private partnership that undergirded the Lung-MAP trial for almost a decade may serve as a model for future clinical research that is more rapid, innovative, and inclusive, according to a recent report published by Herbst et al in Clinical Cancer Research. Background The Lung-MAP...
Consuming Navy Beans May Improve Gut Health, Regulate Immune and Inflammatory Processes in Colorectal Cancer Survivors
Researchers have uncovered that the regular consumption of navy beans may help modulate markers linked to obesity and disease and improve the gut microbiome in colorectal cancer survivors, according to a novel study published by Zhang et al in eBioMedicine. Background Obesity, poor diet, and...
Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows
Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4). Background Early...
Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
In the phase II SPRINT trial reported in the Journal of Clinical Oncology, Ohri et al found that a chemotherapy-sparing regimen of pembrolizumab with risk-adapted radiotherapy was associated with good outcomes in patients with stage III or unresectable stage II non–small cell lung cancer (NSCLC)...
Highlights From the ESMO Congress 2023
The European Society for Medical Oncology (ESMO) Congress 2023 held in Madrid reported out several eagerly awaited and potentially practice-changing trials, bringing forward promising new combination strategies in the targeted and immunotherapy space, and put to the test selective agents against...
Expert Point of View: Elizabeth Smyth, MD
Invited discussant, Elizabeth Smyth, MD, a consultant in gastrointestinal oncology at the Oxford University Hospitals NHS Foundation Trust in the United Kingdom, commented on the notable impact in pathologic complete response rates with the addition of checkpoint inhibitors in MATTERHORN and...
Expert Point of View: Andrea Apolo, MD
Invited discussant Andrea Apolo, MD, of the National Cancer Institute in Bethesda, Maryland, emphasized that the EV-302/KEYNOTE-A39 and CheckMate 901 trials mark a significant achievement. “Outperforming chemotherapy in first-line therapy is monumental for our field. The two studies presented are...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
The invited discussant of TROPION-Breast01, Sarat Chandarlapaty, MD, PhD, Member of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, New York, said the results suggest datopotamab deruxtecan (Dato-DXd) may be a good treatment option for a subset of patients,...
Expert Point of View: Laura Locati, MD, PhD
Invited discussant of the LIBRETTO-531 trial, Laura Locati, MD, PhD, Associate Professor of Medical Oncology, Department of Internal Medicine and Therapeutics, University of Pavia and Medical Oncology Unit, Istituti Clinici Scientifici Maugeri IRCCS, Italy, commented: “Selpercatinib is a new...
Expert Point of View: Sarat Chandarlapaty, MD, PhD
Invited discussant of TROPION-Lung01, Sarat Chandarlapaty, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, was cautiously optimistic about this new treatment option. “Dato-DXd [datopotamab deruxtecan] has a benefit over standard-of-care docetaxel in the second-line setting. There...
Antibody-Drug Conjugate Makes Progress as Second-Line Therapy for Advanced NSCLC
Datopotamab deruxtecan (Dato-DXd), a TROP-2–directed antibody-drug conjugate, improved progression-free survival by 25% on blinded independent committee review in previously treated patients with advanced or metastatic non–small cell lung cancer (NSCLC), and it was reported to be less toxic than...
Novel AI Model May Predict Nonsmokers at High Risk for Lung Cancer
An artificial intelligence (AI) model may be capable of using routine chest x-ray images to identify nonsmokers who may be at high risk for lung cancer, according to new findings presented by Walia et al at the Radiological Society of North American (RSNA) 2023 Scientific Assembly and Annual...
